Citi Starts Intellia Therapeutics (NTLA) at Sell
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $20.01 -5.48%
Rating Summary:
27 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
27 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Citi analyst David Lebowitz initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Sell rating and a price target of $50.00.
For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.
Shares of Intellia Therapeutics closed at $60.06 yesterday.
You May Also Be Interested In
- H.C. Wainwright Starts Processa Pharmaceuticals (PCSA) at Buy
- Bernstein SocGen Group Starts General Motors (GM) at Outperform
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
